Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920801 | 0.82 | TAAR1 (0.68) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL3164681 | 0.82 | TAAR1 (0.68) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL3165373 | 0.82 | TAAR1 (0.68) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL2466732 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL4776175 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL6298733 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL4776719 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL2472567 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL2471283 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5KDM4EMEN1 | |
| SCHEMBL2469427 | 0.82 | TAAR1 (0.70) | TAAR1KLK1KLK5MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101528709-A | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | claimed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | claimed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-0564356-A1 | 4-phenylaminomethylimidazole derivatives, process for their preparation, angiotensin II receptor antagonists and their application in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1993-10-06 | — | — | EP | claimed |
| CN-101528709-B | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-01 | — | — | CN | disclosed |
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| CN-101528709-A | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-7279497-B2 | Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-10-09 | — | — | US | disclosed |
| US-5837702-A | HAVING POTASSIUM CHANNEL ACTIVATING ACTIVITY USEFUL AS CARDIOVASCULAR AGENTS AND TREATMENT OF ISCHEMIA | BRISTOL-MYERS SQUIBB CO. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0648758-A1 | 4-Arylamino-benzopyran and related compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0564356-A1 | 4-phenylaminomethylimidazole derivatives, process for their preparation, angiotensin II receptor antagonists and their application in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1993-10-06 | — | — | EP | disclosed |
| EP-0564356-A1 | 4-phenylaminomethylimidazole derivatives, process for their preparation, angiotensin II receptor antagonists and their application in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1993-10-06 | — | — | EP | disclosed |
| EP-0081324-B1 | SUBSTITUTED PHARMACOLOGICALLY ACITVE IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HTR2C, AHR, HAX1 | TAAR1 60/4885KLK1 3778/4885KLK5 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.